<DOC>
	<DOCNO>NCT00000987</DOCNO>
	<brief_summary>To study safety maximum tolerate dose ( MTD ) combine chemotherapy administer patient advance Kaposi 's sarcoma together one two different dos zidovudine ( AZT ) . The combination AZT chemotherapy may effective treat tumor well prevent life-threatening infection use patient AIDS Kaposi 's sarcoma . The MTD combine chemotherapy determine information available future study , relative effectiveness two dos AZT learn .</brief_summary>
	<brief_title>A Study Chemotherapy Plus Azidothymidine Treatment Kaposi 's Sarcoma Patients With AIDS</brief_title>
	<detailed_description>The combination AZT chemotherapy may effective treat tumor well prevent life-threatening infection use patient AIDS Kaposi 's sarcoma . The MTD combine chemotherapy determine information available future study , relative effectiveness two dos AZT learn . AMENDED : AZT mouth . If treatment well tolerate , subsequent group patient start increase dos doxorubicin combine dose bleomycin vincristine . After determination MTD chemotherapy combination AZT , 2nd phase begin AZT give first group patient give bleomycin vincristine . If combination well tolerate , subsequent group start increase dos doxorubicin dose bleomycin , vincristine AZT . The MTD chemotherapy combination AZT determine . Patients achieve maximum response tumor maintain AZT alone . This outpatient study , patient see every 2 week evaluation , physical examination every month . Original design : The combination chemotherapy AZT give group four patient , first group begin bleomycin vincristine , without addition doxorubicin . The chemotherapy give intravenously every 2 week . This combine first AZT mouth .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Sarcoma , Kaposi</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Bleomycin</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Medication grade 1 2 oral toxicity . Antiemetic agent , except steroid , gastrointestinal toxicity . Toxicity grade accord NIAID Recommendations Grading Acute Subacute Toxic Effects ( Adults ) . Patients must demonstrate follow clinical laboratory finding : 25 mucocutaneous lesion without lymphedema . Progressive Kaposi 's sarcoma ( KS ) 10 new lesion month prior study entry visceral involvement . Oral mucosal lesion ( ) require therapy . Prior history Pneumocystis carinii pneumonia ( PCP ) Mycobacterium avium intracellulare . Patients follow constitutional symptom etiology establish may include : Temperature &gt; 38 degree C and/or drench night sweat 1 month . Watery diarrhea ( = &gt; 3 stools/day ) 2 week . Weight loss &gt; 10 percent normal . Patients carcinoma situ cervix localize squamous basal cell carcinoma skin may include . Active alcohol drug abuse sufficient prevent adequate compliance study therapy . Exclusion Criteria Coexisting Condition : Patients follow condition exclude : Peripheral sensory motor neuropathy . Opportunistic infection require therapy . Significant pulmonary ( exertional dyspnea minimal exercise ) cardiac insufficiency ( New York Heart Association , status &gt; 2 ) . Serious neuropsychiatric illness would prevent informed consent intensive treatment . Concurrent Medication : Excluded : Any drug cause anemia , neutropenia , significant risk nephrotoxicity . Patients history systemic malignancy lymphomas , except carcinoma situ cervix localize squamous basal cell carcinoma skin , exclude study . Prior Medication : Excluded : Systemic antineoplastic chemotherapy . Excluded within 30 day study entry : Any investigational therapy . Antiretroviral agent ( zidovudine , ribavirin ) . Immunomodulating agent ( steroid , interferon , naltrexone , isoprinosine , interleukin2 ) .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Vincristine</keyword>
	<keyword>Doxorubicin</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Zidovudine</keyword>
	<keyword>Bleomycin</keyword>
</DOC>